If the current investment momentum persists, 2024 could surpass the year-end totals seen in 2019 and 2023, which were $8.2 billion and $10.7 billion respectively, according to Rock Health's H1 2024 digital health funding report. In the first half of 2024, U.S. digital health startups raised $5.7 billion across 266 deals. Seed, Series A, and Series B funding made up 84% of these investments, with Series A funding being the most common. Notably, 38% of the Series A funds were allocated to startups leveraging artificial intelligence, with AI-driven companies receiving 34% of the total digital health funding in H1 2024.
The trend of unlabeled deals, which continued from early 2023, saw 40% (or 107 deals) of H1 2024 being unlabeled compared to 44% in 2023. The occurrence of unlabeled deals has been gradually increasing since 2019, starting at 4% and rising to 22% by 2022. These deals typically happen when startups need capital but don’t meet benchmarks for their next labeled raise or want to delay valuation discussions. However, unlabeled raises have declined in 2024, dropping from 47% in Q1 to 33% in Q2, as previously predicted by Rock Health.
Digital health companies focusing on disease treatments received the highest funding by value proposition, totaling $1.1 billion, while mental health topped the highest-funded clinical indications list with $682 million raised. H1 2024 saw three exits from digital health companies, including Waystar, Nuvo, and Tempus AI, marking the first exits in 21 months within the sector. While acquisitions by fellow digital health firms decreased to 34 deals in H1 2024 compared to 83 in 2023, private equity firms acquired ten digital health startups, surpassing the total for 2023 and potentially exceeding 2021 and 2022 totals. The report suggests that the digital health sector continues to show resilience and adaptability, with funding momentum and the decline in unlabeled rounds hinting at a return to more sustainable venture patterns.
Click here to read the original news story.